Solgekma 38mg/ml concentrato per soluzione per infusione clinical trials

Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population

This study is testing a new combination of treatments, including a drug called toripalimab, for a type of cancer called nasopharyngeal cancer that has come back or spread. Doctors want to see if this new treatment is safe and works well for people outside of areas where the cancer is common.